Spots Global Cancer Trial Database for best supportive care (bsc)
Every month we try and update this database with for best supportive care (bsc) cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| A Study Comparing Siltuximab Plus Best Supportive Care to Placebo Plus Best Supportive Care in Anemic Patients With International Prognostic Scoring System Low- or Intermediate-1-Risk Myelodysplastic Syndrome | NCT01513317 | Myelodysplastic... | Siltuximab Placebo Best supportive... | 18 Years - | Janssen Research & Development, LLC | |
| Controlled Study of Rigosertib Versus Physician's Choice of Treatment in MDS Patients After Failure of an HMA | NCT02562443 | Myelodysplastic... MDS Refractory Anem... RAEB | rigosertib Any approved or... best supportive... best supportive... | 18 Years - 81 Years | Traws Pharma, Inc. | |
| Global Study Looking at the Combination of RAD001 Plus Best Supportive Care (BSC) and Placebo Plus BSC to Treat Patients With Advanced Hepatocellular Carcinoma. | NCT01035229 | Carcinoma | Everolimus Everolimus Plac... Best Supportive... | 18 Years - | Novartis | |
| An Efficacy Study in Gastric and Gastroesophageal Junction Cancer Comparing Ipilimumab Versus Standard of Care Immediately Following First Line Chemotherapy | NCT01585987 | Locally Advance... | Ipilimumab Best Supportive... | 18 Years - | Bristol-Myers Squibb | |
| Tax First-line Chemotherapy With Different Doses and Then Maintenance Therapy | NCT01038661 | Lung Neoplasms | Docetaxel Cisplatin Best supportive... | 18 Years - 75 Years | Sanofi | |
| A Study to Evaluate the Efficacy and Safety of CNTO328 Plus Best Supportive Care in Multicentric Castleman's Disease | NCT01024036 | Multicentric Ca... | Siltuximab Placebo Best Supportive... | 18 Years - | Janssen Research & Development, LLC | |
| Controlled Study of Rigosertib Versus Physician's Choice of Treatment in MDS Patients After Failure of an HMA | NCT02562443 | Myelodysplastic... MDS Refractory Anem... RAEB | rigosertib Any approved or... best supportive... best supportive... | 18 Years - 81 Years | Traws Pharma, Inc. | |
| A Study Evaluating Safety and Efficacy of Venetoclax in Combination With Azacitidine Versus Standard of Care After Allogeneic Stem Cell Transplantation (SCT) in Participants With Acute Myeloid Leukemia (AML) | NCT04161885 | Acute Myeloid L... Cancer | Venetoclax Azacitidine Best Supportive... | 12 Years - | AbbVie | |
| Global Study Looking at the Combination of RAD001 Plus Best Supportive Care (BSC) and Placebo Plus BSC to Treat Patients With Advanced Hepatocellular Carcinoma. | NCT01035229 | Carcinoma | Everolimus Everolimus Plac... Best Supportive... | 18 Years - | Novartis | |
| Study of IMC-1121B (Ramucirumab) With Best Supportive Care in Participants With Gastric Cancer and Adenocarcinoma | NCT00917384 | Gastric Cancer Adenocarcinoma | ramucirumab Placebo Best Supportive... | 18 Years - | Eli Lilly and Company | |
| Cancer Vaccine Study for Stage III, Unresectable, Non-small Cell Lung Cancer (NSCLC) in the Asian Population | NCT01015443 | Non-Small Cell ... | Tecemotide Single low dose... Placebo Saline Best Supportive... | 18 Years - | Merck KGaA, Darmstadt, Germany | |
| Comparison of Survival Benefit of Panitumumab With Supportive Care to Best Supportive Care Alone in Patients With Metastatic Colorectal Cancer | NCT01412957 | Metastatic Colo... | Best Supportive... Panitumumab | 18 Years - | Amgen | |
| A Study of Oral Venetoclax Tablets and Oral Azacitidine Versus Oral Azacitidine as Maintenance Therapy in Adult Participants With Acute Myeloid Leukemia in First Remission After Conventional Chemotherapy | NCT04102020 | Acute Myeloid L... | Venetoclax Azacitidine CC-486 | 18 Years - | AbbVie | |
| Effects of Maintenance Cabozantinib+BSC Versus BSC in Children and AYA With Osteosarcoma | NCT06341712 | Osteosarcoma Osteosarcoma in... Osteosarcoma in... | Cabozantinib Best Supportive... Best Supportive... | 5 Years - 30 Years | Ipsen | |
| A Study Comparing Siltuximab Plus Best Supportive Care to Placebo Plus Best Supportive Care in Anemic Patients With International Prognostic Scoring System Low- or Intermediate-1-Risk Myelodysplastic Syndrome | NCT01513317 | Myelodysplastic... | Siltuximab Placebo Best supportive... | 18 Years - | Janssen Research & Development, LLC | |
| Phase 2b Randomized Controlled Study of Tecemotide (L-BLP25) for Immunotherapy of NSCLC (Non-Small Cell Lung Cancer) | NCT00157209 | Lung Neoplasms Carcinoma, Non-... | Tecemotide (L-B... Single low dose... Best Supportive... | 18 Years - | Merck KGaA, Darmstadt, Germany | |
| Comparison of Survival Benefit of Panitumumab With Supportive Care to Best Supportive Care Alone in Patients With Metastatic Colorectal Cancer | NCT01412957 | Metastatic Colo... | Best Supportive... Panitumumab | 18 Years - | Amgen | |
| Study of Pembrolizumab (MK-3475) or Placebo Given With Best Supportive Care in Asian Participants With Previously Treated Advanced Hepatocellular Carcinoma (MK-3475-394/KEYNOTE-394) | NCT03062358 | Carcinoma, Hepa... | pembrolizumab placebo best supportive... | 18 Years - | Merck Sharp & Dohme LLC | |
| A Study Evaluating Safety and Efficacy of Venetoclax in Combination With Azacitidine Versus Standard of Care After Allogeneic Stem Cell Transplantation (SCT) in Participants With Acute Myeloid Leukemia (AML) | NCT04161885 | Acute Myeloid L... Cancer | Venetoclax Azacitidine Best Supportive... | 12 Years - | AbbVie | |
| A Study to Evaluate the Efficacy and Safety of CNTO328 Plus Best Supportive Care in Multicentric Castleman's Disease | NCT01024036 | Multicentric Ca... | Siltuximab Placebo Best Supportive... | 18 Years - | Janssen Research & Development, LLC | |
| A Study of Oral Venetoclax Tablets and Oral Azacitidine Versus Oral Azacitidine as Maintenance Therapy in Adult Participants With Acute Myeloid Leukemia in First Remission After Conventional Chemotherapy | NCT04102020 | Acute Myeloid L... | Venetoclax Azacitidine CC-486 | 18 Years - | AbbVie | |
| Safety and Efficacy of RAD001 (Everolimus) Monotherapy Plus Best Supportive Care in Patients With Advanced Gastric Cancer (AGC) | NCT00879333 | Advanced Gastri... | Everolimus Everolimus plac... Best Supportive... | 18 Years - | Novartis | |
| Cancer Vaccine Study for Stage III, Unresectable, Non-small Cell Lung Cancer (NSCLC) in the Asian Population | NCT01015443 | Non-Small Cell ... | Tecemotide Single low dose... Placebo Saline Best Supportive... | 18 Years - | Merck KGaA, Darmstadt, Germany | |
| Safety and Efficacy of RAD001 (Everolimus) Monotherapy Plus Best Supportive Care in Patients With Advanced Gastric Cancer (AGC) | NCT00879333 | Advanced Gastri... | Everolimus Everolimus plac... Best Supportive... | 18 Years - | Novartis |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
